NPHCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
NUTRA PHARMA CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $806.69K
- P/E (TTM)
- –
- Dividend yield
- –
Nutra Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Market Cap | $715.97K | $164.85M |
| Enterprise Value | $13.27M | $87.06M |
| PS Ratio | 4.45 | 3.60 |
Enterprise value
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| EV / Sales | 82.53 | 2.43 |
Income (trailing twelve months)
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Revenue | $160.82K | $57.94M |
| Gross Profit | $104.27K | $90.47M |
| Operating Income | -$1.64M | -$21.44M |
| Pretax Income | -$5.42M | -$14.45M |
| Net Income | -$5.42M | -$22.46M |
| EBITDA | -$1.64M | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Margins
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Gross Margin | 64.8% | 52.3% |
| Operating Margin | -1017.8% | -44.5% |
| Pretax Margin | -3370.6% | -13.0% |
| Profit Margin | -3370.6% | -39.2% |
| EBITDA Margin | -1017.8% | -31.3% |
Returns
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | -731.5% | -41.0% |
Growth
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -49.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 20.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 37.8% | 6.42% |
Balance sheet
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $17.60K | $62.42M |
| Total Debt | $12.57M | $120.13M |
| Net Cash (Debt) | -$12.56M | $15.68M |
| Net Cash Per Share | -$0.00 | $0.66 |
| Equity (Book Value) | -$21.21M | $48.79M |
| Book Value Per Share | -$0.00 | $1.36 |
| Tangible Book Value | -$21.21M | $23.06M |
| Working Capital | -$21.23M | $75.77M |
Financial position
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Current Ratio | 0.02 | 3.30 |
| Quick Ratio | 0.00 | 2.39 |
| Interest Coverage | -68.24 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.05M | -$12.35M |
Efficiency
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.22 | 0.38 |
| Inventory Turnover | 7.90 | 2.67 |
| Revenue Per Employee | $22.97K | $398.96K |
| Profits Per Employee | -$774.36K | -$703.34K |
| Employee Count | 7 | 74 |
Dividends and yields
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Earnings Yield | -757.1% | -22.7% |
Shares
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 7,159,730,000 | 58,179,650 |
| Shares Change (YoY) | -47.7% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 7,147,730,000 | 49,173,100 |
| Shares Held by Insiders | 0.17% | 11.6% |
Scores
| Measure | Nutra Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -235.16 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Nutra Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.